A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy
A study for patients with glioblastoma using study drug ICT-107
Sponsor: ImmunoCellular Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAQ1305
U.S. Govt. ID: NCT02546102
Contact: Fabio Iwamoto: 212-342-0571 / fi2146@cumc.columbia.edu
Additional Study Information: This is a research study to test the effectiveness of ICT-107, an experimental drug, with the standard of care (SOC) for treatment of glioblastoma compared to enriched blood cells (PBMC) with the SOC. The study will enroll 400 subjects age 18 years and older with newly diagnosed glioblastoma. Following an initial SOC radiation treatment, patients will be randomly assigned in a 1:1 ratio to receive either the ICT-107 with SOC or PBMC with SOC. Several survival rates will be used to determine the effectiveness of the new drug. Given the limited success of the current standard of care, ICT-107 has the potential for improving the outcome of patients with glioblastoma.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Do you have a confirmed initial diagnosis of glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Fabio Iwamoto